jeudi 31 janvier 2019

Onco Actu du 31 janvier 2019


1. BIOLOGIE



Study reveals how brain tumors escape the effects of antiangiogenic drugs [Mass. General Hospital]











Is it time to change the reference genome? [bioRxiv]











Glioblastoma Study Highlights Sex Differences in Brain Cancer [NCI]











3.1 PRÉVENTION - TABAC



American Lung Association's 'State of Tobacco Control' Report Finds States, Federal Government Failed to Act to Prevent, Reduce Tobacco Use [American Lung Association]











Federal, state governments failed to prevent smoking, report says [UPI]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Vaping twice as likely as gum to help smokers quit, research finds [The Guardian]











E-cigarettes almost twice as effective as nicotine replacement therapies for quitting smoking, says trial [Cancer Research UK]











E-cigarettes more effective than nicotine replacement to help smokers quit, study finds [Washington Post]











E-Cigarettes Are Effective at Helping Smokers Quit, a Study Says [NY Times]










E-cigs outperform patches and gums in quit-smoking study [AP]











The Dangerous Flavors of E-Cigarettes [NEJM]










3.2 PRÉVENTION - OBÉSITÉ



Food industry sway over public health gets new scrutiny [AP]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



A nagging sore throat may be an early sign of cancer [NHS Choices]










4.12 BIOPSIES LIQUIDES



Lucence Diagnostics Opens New Headquarters and Molecular Diagnostics Laboratory in Singapore [Lucence]











5. TRAITEMENTS



Roswell Park Researchers Propose Two New Strategies for Treating Pancreatic Cancer [Roswell Park]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



New target for gastric cancer therapies [Cardiff University]











‘Cancer cure’ doubted as Israeli team claims it can’t afford to publish findings [The Times of Israel]











MuTaTo: Is an Israeli company within a year of a “complete cure for cancer”? [Respectful Insolence]










5.10 TRAITEMENTS - ESSAIS



Pfizer's Xtandi blows by Johnson & Johnson's Erleada with hot start in new prostate cancer field [Fierce Pharma]











Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer [Janssen]











J&J scores another PhIII win for Erleada as it continues to build a blockbuster franchise [EndPoints]










5.12 IMMUNOTHÉRAPIES



It Was Supposed to Work: Managing Disappointment When Promising Treatments Fail [ASCO Connection]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



First child given pioneering CAR-T cancer therapy [BBC News]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs [Xconomy]











5.2 PHARMA



Novartis lays out blockbuster launches for 2018-2020, with surprising inclusion of Kymriah [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA moving to 'risk-based' inspections even as valsartan scare adds new wrinkle to oversight [Fierce Pharma]











How a Tainted Heart Drug Made in China Slipped Past the FDA [Bloomberg]










Exclusive Interview: FDA Commissioner Talks Drug Pricing, Expanded Access, and Tobacco [ASCO in Action Podcast]











6.6 PUBLICATIONS



Can a “nudge” stop researchers from using the wrong cell lines? [Retraction Watch]











Encouraging Data Sharing: A Small Investment for Large Potential Gain [The Scholarly Kitchen]











6.7.2 APPLIS



The initiative of EORTC staff members to help parents of children with cancer or stem cell therapies [EORTC]